SCHEMBL3528024

SCHEMBL3528024

CCOC(=O)c1cnc(SC)nc1N(CCC#N)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.53
▸ TDP1 Q9NUW8 3/20 0.53
▸ POLB P06746 1/20 0.53
▸ MAPT P10636 7/20 0.48
▸ HPGD P15428 2/20 0.48
▸ SMN1; SMN2 Q16637 6/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ SYK P43405 2/20 0.44
▸ MAPK1 P28482 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ TSHR P16473 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11020556 0.86 ALDH1A1 (0.55) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL11015988 0.77 ALDH1A1 (0.47) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL3723384 0.77 ALDH1A1 (0.56) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL11020554 0.77 ALDH1A1 (0.56) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL11021116 0.77 HTT (0.48) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL4260559 0.73 MEN1 (0.56) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL3532279 0.72 ALDH1A1 (0.56) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL3442518 0.72 ALDH1A1 (0.70) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL11584085 0.71 MEN1 (0.54) ALDH1A1TDP1POLBMAPTHPGD
SCHEMBL3294463 0.70 MEN1 (0.45) ALDH1A1TDP1POLBMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 — — US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 — — EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 — — WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR ALDH1A1 3590/4885TDP1 869/4885POLB 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback